Company: VERA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-314244
Chunk: 22

Company: Vera Therapeutics, Inc.
Filing Date: 2025-12-10
Form: 424B5
Chunk 22
---
 supplement, other than the shares of our Class A common stock to be sold in this offering.

The restrictions on our actions, as described above, do
not apply to certain transactions, including (i) the issuance of shares of Class A common stock or securities convertible into or exercisable for shares of our Class A common stock pursuant to the conversion or exchange of convertible
or exchangeable securities or the exercise of warrants or options (including net exercise) or the settlement of restricted stock units (including net settlement), in each case outstanding on the date of the underwriting agreement and described in
this prospectus supplement; (ii) grants of stock options, stock awards, restricted stock, restricted stock units, or other equity awards and the issuance of shares of our Class A common stock or securities convertible into or exercisable
or exchangeable for shares of our Class A common stock (whether upon the exercise of stock options or otherwise) to our employees, officers, directors, advisors, or consultants pursuant to the terms of an equity compensation plan in effect as
of the closing of this offering and described in this prospectus supplement; (iii) grants of inducement awards and the issuance of shares of our Class A common stock or securities convertible into or exercisable or exchangeable for shares
of our Class A common stock (whether upon the exercise of inducement awards or otherwise) to persons not previously one of our employees or directors, or following a bona fide period of non-employment, as
an inducement material to such persons entering into employment with us pursuant to the terms of an inducement plan that we may adopt, as described in this prospectus supplement; (iv) the issuance of up to 10% of the outstanding shares of our
Class A common stock, or securities convertible into, exercisable for, or which are otherwise exchangeable for, our Class A common stock, immediately following the closing of this offering, in acquisitions or other similar strategic
transactions, provided that such recipients enter into a lock-up agreement with the underwriters; (v) our filing of any registration statement on Form S-8 relating
to securities granted or to be granted pursuant to any plan in effect on the date of the underwriting agreement and described in this prospectus supplement, any plan proposed to be adopted and described in this prospectus supplement or any assumed
benefit plan pursuant to an acquisition or similar strategic transaction; (vi) facilitating the establishment of a trading plan on behalf of a stockholder, officer or director pursuant to